regulator of chromosome condensation 2 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored RCC2P4 profile across patient tissues and cancer cell-line models. RCC2P4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RCC2P4 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, RCC2P4 RNA expression shows 16,361 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where RCC2P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RCC2P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RCC2P4 survival associations across molecular data types. RCC2P4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RCC2P4 RNA expression–survival associations across cancer types. High RCC2P4 expression shows unfavorable associations in ACC, MESO, KICH, LUSC, CHOL and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RCC2P4 RNA expression.
This table summarizes RCC2P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RCC2P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RCC2P4 shows higher tumor expression in COAD and STAD. The COAD box plot shows higher RCC2P4 RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p = .007).
This table shows molecular features associated with RCC2P4 in patient tissues and cancer cell lines. In patient samples, RCC2P4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
